4736.TW TAIDOC TECHNOLOGY CORP
- Market cap
- TWD 13.1B
- P/E
- 5.2x
- P/B
- 1.19x
- ROE
- 23.6%
- Dividend yield
- 7.09%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is 4736.TW undervalued?
Graham number4736.TW trades 47.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TAIDOC TECHNOLOGY CORP fundamental analysis
No fundamental analysis for TAIDOC TECHNOLOGY CORP yet.
TAIDOC TECHNOLOGY CORP stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TAIDOC TECHNOLOGY CORP
TaiDoc Technology Corporation manufactures and markets medical devices in Taiwan and internationally. The company offers In vitro diagnostics products, including multiple parameter monitoring systems, point of care testing devices, and lancet and lancing devices; vet health care products comprise blood glucose and calcium meters, and blood ketone meters; and medical devices, such as nebulizers, thermometers, blood pressure monitors, vital sign monitors, and pulse oximeters. …
Full company profileTAIDOC TECHNOLOGY CORP financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
TAIDOC TECHNOLOGY CORP annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.15B | 3.34B | 4.35B | 4.14B | 5.90B | 6.49B | 9.63B | 4.81B | 4.64B | 4.20B | 4.20B |
| Gross Profit | 1.46B | 1.45B | 1.98B | 1.83B | 2.95B | 3.21B | 5.65B | 2.07B | 2.05B | 1.93B | 1.84B |
| Operating Income | 629M | 634M | 1.06B | 803M | 1.90B | 2.12B | 4.21B | 968M | 805M | 956M | 828M |
| EBITDA | 817M | 837M | 1.32B | 1.07B | 2.23B | 2.74B | 4.61B | 1.19B | 1.65B | 1.10B | 250M |
| Net Income | 489M | 425M | 877M | 664M | 1.52B | 1.97B | 3.38B | 1.02B | 1.16B | 1.44B | 2.60B |
| EPS | 5.91 | 5.08 | 10 | 7.56 | 16 | 21 | 35 | 11 | 12 | 15 | 27 |
| Balance Sheet | |||||||||||
| Total Assets | 5.07B | 6.06B | 7.53B | 7.83B | 9.17B | 10.5B | 12.9B | 11.9B | 12.2B | 12.8B | 14.4B |
| Total Liabilities | 1.99B | 2.89B | 3.51B | 3.32B | 2.55B | 2.89B | 2.91B | 2.65B | 2.72B | 2.66B | 3.02B |
| Shareholders' Equity | 2.98B | 3.05B | 3.88B | 4.37B | 6.43B | 7.39B | 9.67B | 8.90B | 9.09B | 9.79B | 11.0B |
| Cash & Short-term Investments | 1.56B | 1.77B | 1.65B | 2.20B | 2.31B | 3.08B | 5.03B | 4.73B | 4.94B | 5.23B | 6.26B |
| Total Debt | 1.21B | 2.09B | 2.30B | 2.34B | 907M | 1.26B | 636M | 1.09B | 1.05B | 1.16B | 941M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 636M | 521M | 783M | 1.09B | 1.68B | 1.92B | 3.21B | 1.17B | -181M | 853M | 1.11B |
| Capital Expenditure | 211M | 172M | 1.04B | 309M | 644M | 327M | 508M | 114M | 355M | 251M | 330M |
| Free Cash Flow | 425M | 349M | -262M | 778M | 1.04B | 1.59B | 2.70B | 1.06B | -537M | 602M | 779M |
| Ratios | |||||||||||
| ROE | 16.4% | 13.9% | 22.6% | 15.2% | 23.7% | 26.7% | 35.0% | 11.4% | 12.8% | 14.7% | 23.6% |
| ROA | 9.7% | 7.0% | 11.6% | 8.5% | 16.6% | 18.8% | 26.2% | 8.5% | 9.5% | 11.3% | 18.1% |
| Net Profit Margin | 15.5% | 12.7% | 20.2% | 16.0% | 25.8% | 30.4% | 35.1% | 21.2% | 25.0% | 34.3% | 61.9% |
| Debt to Equity | 0.41x | 0.69x | 0.59x | 0.53x | 0.14x | 0.17x | 0.07x | 0.12x | 0.12x | 0.12x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
TAIDOC TECHNOLOGY CORP dividends
- Dividend yield
- 7.09%
- Forward dividend
- 5.07 TWD
- Payout ratio
- 64.2%
- Ex-dividend date
- Aug 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 926M | 9.57 | 64.2% |
| 2024 | TWD 954M | 9.96 | 82.3% |
| 2023 | TWD 1.91B | 20 | 187.3% |
| 2022 | TWD 1.40B | 14 | 41.3% |
| 2021 | TWD 1.06B | 11 | 53.7% |
| 2020 | TWD 590M | 6.33 | 38.8% |
| 2019 | 599M | 6.82 | 90.2% |
| 2018 | 380M | 4.54 | 43.3% |
| 2017 | 355M | 4.24 | 83.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1101.4186:1000 on Aug 27, 2026.
Who owns TAIDOC TECHNOLOGY CORP
- Insiders 45.49%
- Institutions 5.58%
- Public & others 48.93%
- Shares outstanding 104M
- Free float 57.1M
TAIDOC TECHNOLOGY CORP company profile
- Company name
- TAIDOC TECHNOLOGY CORP
- Ticker
- 4736.TW
- ISIN
- TW0004736004
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Fiscal year end
- September
- Address
- No. 127, Wugong 2nd Road, New Taipei City, Taiwan, 24888
- Phone
- 886 2 6625 8188
- Website
- taidoc.com
About TAIDOC TECHNOLOGY CORP
TaiDoc Technology Corporation manufactures and markets medical devices in Taiwan and internationally. The company offers In vitro diagnostics products, including multiple parameter monitoring systems, point of care testing devices, and lancet and lancing devices; vet health care products comprise blood glucose and calcium meters, and blood ketone meters; and medical devices, such as nebulizers, thermometers, blood pressure monitors, vital sign monitors, and pulse oximeters. It also provides telehealth remote monitoring devices and smartphone applications; and Covid-19 antigen rapid test kits. In addition, the company offers services for regulatory professionals, as well as in the areas of clinical suggestions, engineering resources, and manufacturing systems. Further, the company provides various applications, including MyLink, ProCheck, Healthy Check, Healthy Check PRO, PCLink, and USB adapter driver. TaiDoc Technology Corporation was founded in 1998 and is headquartered in New Taipei City, Taiwan.
TAIDOC TECHNOLOGY CORP management
5- Mr. Chaowang ChenChairman of the Board, GM & President
- Ms. Qiting HuangAssociate Manager of Financial & Accounting, Chief Accountant and Accounting Supervisor
- Mr. Hong-Zhi JiExecutive VP of Sales Division & Director
- Ms. Jia-Qi WuDeputy General Manager
- Mr. Tai-Cheng ZhouDeputy General Manager